Literature DB >> 15707893

Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1.

Irina N Krylova1, Elena P Sablin, Jamie Moore, Robert X Xu, Gregory M Waitt, J Andrew MacKay, Dalia Juzumiene, Jane M Bynum, Kevin Madauss, Valerie Montana, Lioudmila Lebedeva, Miyuki Suzawa, Jon D Williams, Shawn P Williams, Rodney K Guy, Joseph W Thornton, Robert J Fletterick, Timothy M Willson, Holly A Ingraham.   

Abstract

Vertebrate members of the nuclear receptor NR5A subfamily, which includes steroidogenic factor 1 (SF-1) and liver receptor homolog 1 (LRH-1), regulate crucial aspects of development, endocrine homeostasis, and metabolism. Mouse LRH-1 is believed to be a ligand-independent transcription factor with a large and empty hydrophobic pocket. Here we present structural and biochemical data for three other NR5A members-mouse and human SF-1 and human LRH-1-which reveal that these receptors bind phosphatidyl inositol second messengers and that ligand binding is required for maximal activity. Evolutionary analysis of structure-function relationships across the SF-1/LRH-1 subfamily indicates that ligand binding is the ancestral state of NR5A receptors and was uniquely diminished or altered in the rodent LRH-1 lineage. We propose that phospholipids regulate gene expression by directly binding to NR5A nuclear receptors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15707893     DOI: 10.1016/j.cell.2005.01.024

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  173 in total

1.  Time to face the fats: what can mass spectrometry reveal about the structure of lipids and their interactions with proteins?

Authors:  Simon H J Brown; Todd W Mitchell; Aaron J Oakley; Huong T Pham; Stephen J Blanksby
Journal:  J Am Soc Mass Spectrom       Date:  2012-06-06       Impact factor: 3.109

Review 2.  Aromatase, breast cancer and obesity: a complex interaction.

Authors:  Serdar E Bulun; Dong Chen; Irene Moy; David C Brooks; Hong Zhao
Journal:  Trends Endocrinol Metab       Date:  2011-12-12       Impact factor: 12.015

Review 3.  Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity.

Authors:  Thomas P Burris; Scott A Busby; Patrick R Griffin
Journal:  Chem Biol       Date:  2012-01-27

4.  Antidiabetic phospholipid-nuclear receptor complex reveals the mechanism for phospholipid-driven gene regulation.

Authors:  Paul M Musille; Manish Pathak; Janelle L Lauer; William H Hudson; Patrick R Griffin; Eric A Ortlund
Journal:  Nat Struct Mol Biol       Date:  2012-04-15       Impact factor: 15.369

Review 5.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

6.  Challenges in studying phospholipid signaling.

Authors:  Carsten Schultz
Journal:  Nat Chem Biol       Date:  2010-07       Impact factor: 15.040

Review 7.  Emerging actions of the nuclear receptor LRH-1 in the gut.

Authors:  Pablo J Fernandez-Marcos; Johan Auwerx; Kristina Schoonjans
Journal:  Biochim Biophys Acta       Date:  2010-12-29

Review 8.  Endogenous ligands for nuclear receptors: digging deeper.

Authors:  Michael Schupp; Mitchell A Lazar
Journal:  J Biol Chem       Date:  2010-10-18       Impact factor: 5.157

9.  E3 ubiquitin ligase RNF31 cooperates with DAX-1 in transcriptional repression of steroidogenesis.

Authors:  Anna Ehrlund; Elin Holter Anthonisen; Nina Gustafsson; Nicolas Venteclef; Kirsten Robertson Remen; Anastasios E Damdimopoulos; Anastasia Galeeva; Markku Pelto-Huikko; Enzo Lalli; Knut R Steffensen; Jan-Ake Gustafsson; Eckardt Treuter
Journal:  Mol Cell Biol       Date:  2009-02-23       Impact factor: 4.272

Review 10.  Differentiation of mesenchymal stem cells into gonad and adrenal steroidogenic cells.

Authors:  Takashi Yazawa; Yoshitaka Imamichi; Kaoru Miyamoto; Akihiro Umezawa; Takanobu Taniguchi
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.